TrialDrug development research2022

Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19.

Yuval Ishay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.